Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
People Restoring Communities’ Matthew Linde discusses transition, mission alignment and the firm's next phase of growth in ...
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...
Where to watch, predicted line-ups, form and quotes for this Champions League knockout phase play-off first leg.
Mark Ogden, Gab Marcotti and Bill Connelly offer their best ideas for how to solve the Champions League's woes.
Knee osteoarthritis continues to be a major source of pain and reduced mobility. Credit: SORASIT SRIKHAM-ON / Shutterstock.com. MEDIPOST has submitted an investigational new drug (IND) amendment to ...
Venture 53 Exits GenLogs as it Targets Next Wave of Freight Tech Disruptors. Exit is Proof of Strategy, Doubles Down ...
Delve into the details of vertical power delivery and how it surmounts the limits of traditional lateral power when it comes to supporting secondary power rails.
Novartis to seek full FDA approval for IgAN drug Vanrafia despite missing ph. 3 kidney function goal
It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...
Infigratinib is an investigational oral therapy designed to directly inhibit FGFR3 protein phosphorylation, addressing the underlying cause of achondroplasia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results